{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:31:54Z","timestamp":1772793114116,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ejim.2016.03.026","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T18:40:19Z","timestamp":1462041619000},"page":"88-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Comparison of low-normal and high-normal IGF-1 target levels during growth hormone replacement therapy: A randomized clinical trial in adult growth hormone deficiency"],"prefix":"10.1016","volume":"31","author":[{"given":"Christa C.","family":"van Bunderen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Lips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine L.","family":"Drent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2016.03.026_bb0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2265.1992.tb02347.x","article-title":"The growth hormone deficiency syndrome in adults","volume":"37","author":"Cuneo","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ejim.2016.03.026_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/er.16.1.63","article-title":"Clinical aspects of growth hormone deficiency in adults","volume":"16","author":"de Boer","year":"1995","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ejim.2016.03.026_bb0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-006-0409-4","article-title":"Acromegaly","volume":"9","author":"Scacchi","year":"2006","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.ejim.2016.03.026_bb0020","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2003-030840","article-title":"Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials","volume":"89","author":"Maison","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"10.1016\/j.ejim.2016.03.026_bb0025","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM198912283212605","article-title":"The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency","volume":"321","author":"Salomon","year":"1989","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejim.2016.03.026_bb0030","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1210\/jc.2009-2570","article-title":"Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control","volume":"95","author":"Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ejim.2016.03.026_bb0035","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1210\/jc.2008-2138","article-title":"Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations","volume":"94","author":"Friedrich","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ejim.2016.03.026_bb0040","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1210\/jc.2004-2088","article-title":"Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke","volume":"90","author":"Johnsen","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ejim.2016.03.026_bb0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/01.CIR.0000027563.44593.CC","article-title":"Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study","volume":"106","author":"Juul","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejim.2016.03.026_bb0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/EJE-07-0600","article-title":"Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients","volume":"158","author":"Schneider","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.ejim.2016.03.026_bb0055","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1210\/jc.2010-0940","article-title":"The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study","volume":"95","author":"van Bunderen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ejim.2016.03.026_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1530\/EJE-12-0784","article-title":"Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study","volume":"168","author":"van Bunderen","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.ejim.2016.03.026_bb0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/eje.0.1500671","article-title":"Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency","volume":"150","author":"Abrahamsen","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ejim.2016.03.026_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ghir.2010.01.003","article-title":"Dose-dependent changes in body composition during growth hormone (GH) treatment in Japanese patients with adult GH deficiency: a randomized, placebo-controlled trial","volume":"20","author":"Chihara","year":"2010","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"10.1016\/j.ejim.2016.03.026_bb0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2265.1997.3271123.x","article-title":"Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults","volume":"47","author":"Johannsson","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ejim.2016.03.026_bb0080","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2010-1204","article-title":"Moderate doses of hGH (0.64 mg\/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function","volume":"96","author":"Newman","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2016.03.026_bb0085","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2016.03.026_bb0090","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","volume":"157","author":"Ho","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.ejim.2016.03.026_bb0095","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1210\/jc.2011-1215","article-title":"Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in Adults","volume":"96","author":"van Bunderen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ejim.2016.03.026_bb0100","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2265.2005.02343.x","article-title":"Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men","volume":"63","author":"Arwert","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.ejim.2016.03.026_bb0105","first-page":"833","article-title":"Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis","volume":"75","author":"de Boer","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ejim.2016.03.026_bb0110","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1530\/EJE-12-0563","article-title":"GH therapy in adult GH deficiency: a review of treatment schedules and the evidence for low starting doses","volume":"168","author":"Gasco","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ejim.2016.03.026_bb0115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4158\/EP.15.6.580","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients\u20142009 update: executive summary of recommendations","volume":"15","author":"Cook","year":"2009","journal-title":"Endocr Pract"},{"issue":"3-4","key":"10.1016\/j.ejim.2016.03.026_bb0120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ghir.2012.04.002","article-title":"Comparison of two dose regimens of growth hormone (GH) with different target IGF-1 levels on glucose metabolism, lipid profile, cardiovascular function and anthropometric parameters in gh-deficient adults","volume":"22","author":"Cenci","year":"2012","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"10.1016\/j.ejim.2016.03.026_bb0125","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","article-title":"Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study","volume":"116","author":"Fox","year":"2007","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejim.2016.03.026_bb0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/eje.1.02179","article-title":"Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults\u2014a KIMS database analysis","volume":"155","author":"Abs","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ejim.2016.03.026_bb0135","first-page":"550","article-title":"Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women","volume":"82","author":"Burman","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2016.03.026_bb0140","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-09-0319","article-title":"Growth hormone replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies","author":"Filipsson","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.ejim.2016.03.026_bb0145","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1210\/jc.2013-1610","article-title":"Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients","volume":"98","author":"Klose","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejim.2016.03.026_bb0150","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2265.2009.03716.x","article-title":"The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis","volume":"72","author":"Widdowson","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.ejim.2016.03.026_bb0155","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1210\/jc.2008-1239","article-title":"The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis","volume":"93","author":"Widdowson","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ejim.2016.03.026_bb0160","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2265.2002.01476.x","article-title":"Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess","volume":"56","author":"Thomas","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.ejim.2016.03.026_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/EJE-11-0558","article-title":"Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis","volume":"166","author":"Hazem","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ejim.2016.03.026_bb0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ghir.2004.11.004","article-title":"The influence of growth hormone (GH) substitution on patient-reported outcomes and cognitive functions in GH-deficient patients: a meta-analysis","volume":"15","author":"Arwert","year":"2005","journal-title":"Growth Horm IGF Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ejim.2016.03.026_bb0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000329191","article-title":"Insulin-like growth factor I: pros and cons of a bioassay","volume":"76","author":"Janssen","year":"2011","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"10.1016\/j.ejim.2016.03.026_bb0180","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1210\/jc.2011-0051","article-title":"Igf-I bioactivity better reflects growth hormone deficiency than total igf-I","volume":"96","author":"Varewijck","year":"2011","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516300462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620516300462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T12:25:10Z","timestamp":1536755110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620516300462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":36,"alternative-id":["S0953620516300462"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2016.03.026","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of low-normal and high-normal IGF-1 target levels during growth hormone replacement therapy: A randomized clinical trial in adult growth hormone deficiency","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2016.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}